BusinessAbeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 30, 2017, 12:32 PM UTC
BusinessAbeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 30, 2017, 12:32 PM UTC
BusinessAbeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 30, 2017, 12:32 PM UTC
BusinessAbeona Therapeutics to Present at Multiple Upcoming ConferencesBy Nasdaq OMXMay 19, 2017, 12:06 PM UTC
BusinessAbeona Therapeutics to Present at Multiple Upcoming ConferencesBy Nasdaq OMXMay 19, 2017, 12:06 PM UTC
BusinessAbeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business HighlightsBy Nasdaq OMXMay 16, 2017, 12:05 PM UTC
BusinessAbeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual MeetingBy Nasdaq OMXMay 8, 2017, 12:05 PM UTC
BusinessAbeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual MeetingBy Nasdaq OMXApr 25, 2017, 12:05 PM UTC
